Empagliflozin for ketosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jan 2021: Trial started, NCT05057806
  2. 27 Sep 2021: Trial registered, NCT05057806

The trials

NCT05057806: SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

State
Under way
Phase
Early Phase 1
People
30 planned
Started
13 Jan 2021
Primary completion
30 Nov 2026
Arms
Empagliflozin Group
Results
None posted
  1. 13 Jan 2021: Trial started
  2. 27 Sep 2021: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.